GlassScriptPhysician profile
William David Hardy
NPI 1760410518
$703,666.23
in general payments reported to CMS, 2019-2025
13 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167K · 2020: $82K · 2021: $56K · 2022: $57K · 2023: $155K · 2024: $117K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $149K · Consulting Fee: $125K · Travel and Lodging: $60K · Food and Beverage: $6,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $149,080.00 |
| Consulting Fee | $124,915.34 |
| Travel and Lodging | $60,253.38 |
| Food and Beverage | $6,789.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $562,592.90 | 2019-2025 | Dovato |
| Janssen Products, LP | $45,168.43 | 2023 | Symtuza |
| Merck Sharp & Dohme LLC | $30,901.42 | 2019-2025 | Delstrigo |
| Glaxosmithkline, LLC. | $18,739.73 | 2022-2024 | |
| Gilead Sciences, INC. | $17,705.63 | 2019-2025 | |
| Emd Serono, INC. | $17,266.83 | 2023-2025 | Serostim |
| Csl Behring | $5,000.00 | 2019 | |
| Theratechnologies INC. | $2,538.52 | 2023 | Trogarzo, Egrifta |
| Actelion Pharmaceuticals US, INC. | $2,320.00 | 2024 | Opsumit |
| Tersera Therapeutics LLC | $688.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $324.41 | 2019-2022 | |
| Janssen Biotech, INC. | $307.48 | 2023 | Symtuza |
| Cook Medical LLC | $112.88 | 2025 | Zenith Alpha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.